Chapter 3 - THE “CONSENT FORM” WAS BUILT FROM THREE DIFFERENT DOCUMENTS, AND ONE PAGE HAD BEEN CREATED AFTER ELLIE’S SURGERY
Maya Foster refused Sonora’s request for a private dinner.
“Why?”
Ellie asked.
“They chose steakhouse.”
Ellie stared.
Maya smiled.
“Kidding.”
Claire did not.
Maya continued.
“Because the conference confrontation is now public, and their first instinct is to move discussion into an informal room where nothing is cleanly structured.”
“Then what?”
“Written preservation notice.”
Another.
“Formal meeting.”
Another.
“No deletion.”
Another.
“No product changes designed to erase origin.”
Good.
The preservation letter went out that afternoon.
To Sonora Neurotech.
Miles Rourke.
Nathan Calder.
Crestwave bankruptcy trustee.
The old Westbrook Medical Electronics records custodian.
Three hospitals that had touched Ellie’s early care.
And the independent accessibility center, because some of Ellie’s later medical data lived there too.
Claire did not object.
That mattered.
A less changed version of Claire might have said:
Westbrook lawyers will handle it.
Now she asked:
“What should my company preserve?”
Maya answered:
“Everything remotely related.”
Claire nodded.
Done.
---
The alleged consent packet was twelve pages.
A forensic document specialist named Dr. Helen Park examined high-resolution copies.
Her findings arrived four days later.
Page one:
Genuine pediatric admission form.
Page two:
Genuine anesthesia acknowledgment.
Page three:
Research authorization.
Different paper stock.
Different scanner characteristics.
Different font-generation profile.
Created digitally approximately eight months after Ellie’s ear procedure.
Claire stared.
“So it didn’t exist when I signed.”
“Not in this form.”
Page four:
A genuine medical photography authorization.
The broad “continuing research” paragraph had been inserted above Claire’s signature.
Page twelve:
Signature sheet.
Claire’s signature copied from the anesthesia form.
Gerald’s signature appeared naturally written.
Not copied.
That mattered.
He likely signed research packet later.
Ellie said:
“He knew.”
Maya answered:
“He signed something containing research language.”
Another.
“That supports knowledge.”
Another.
“We still don’t claim beyond what document shows.”
Facts.
Ellie exhaled.
She had spent half her life around lawyers.
Precision had become family dialect.
---
The creation date of the fake research page bothered everyone.
Eight months after surgery.
Why manufacture consent then?
The original emails between Gerald and Dr. Adrian Voss had discussed “stabilizing” Ellie’s testing profile.
By eight months after insertion, the device was already producing effects.
Maybe they needed retrospective cover.
Then Claire remembered something.
“Insurance audit.”
Maya looked.
“What?”
“Westbrook family trust requested medical certification around that time.”
Because Ellie’s diagnosis affected future trustee authority.
Gerald needed documentation.
If someone reviewed procedure history deeply, absence of consent for experimental device could become explosive.
A retrospective research page could protect.
Maybe.
Not proven.
Then another archive entry appeared.
Miles Rourke had requested access to experimental-device files nine months after surgery.
Reason:
Clinical data consolidation.
There.
Rourke had known records existed decades earlier.
Yet during internal review after Ellie’s device was discovered, he told investigators he had never seen evidence of clinical use.
Maya’s expression hardened.
“That is potentially a false statement.”
Claire said:
“Under oath?”
“Internal interview, not sworn.”
“Still.”
“Yes.”
---
Sonora’s legal team responded with seven pages of confidence.
They argued:
Rourke Technical Holdings acquired Crestwave assets lawfully.
Consent materials appeared facially valid.
Sonora used de-identified data.
The conference mention of “Westbrook pediatric case” referred to a historical research affiliation, not Ellie individually.
Ellie publicly identified herself.
Therefore any loss of anonymity resulted from her own disclosure.
Ellie stared.
“They’re blaming me for saying that was my scan.”
Maya sighed.
“They are making a legal argument.”
“It is a terrible argument.”
“Sometimes those happen too.”
Sonora also insisted Auralink S2 was not derived from unlawful implantation.
It used later patent families, external hardware, and new algorithms.
That might be true.
Important.
Ellie did not want to destroy useful technology merely because predecessor data had unethical history.
So she asked:
“What part of their current product actually depends on my data?”
That became central.
Not:
How do I punish them?
What did they use?
---
An independent biomedical engineer reviewed patents.
Sonora’s current device relied primarily on:
Modern vibration mapping.
External transducers.
Adaptive signal processing.
Machine-learning calibration.
Most developed recently.
However, two foundational claims in Sonora’s regulatory dossier cited “long-duration pediatric tolerance data” from the Westbrook case.
That was Ellie.
They used her years of exposure to claim certain vibration frequencies had not caused structural damage.
Ellie almost became sick.
“I was not being monitored for safety.”
“No,” the engineer said.
“You were living with an undisclosed device.”
“They’re calling that tolerance data.”
“Yes.”
“That’s disgusting.”
“Yes.”
For once no correction needed.
Then:
“Does FDA rely on it?”
“Partially.”
“Would approval collapse without?”
“Not necessarily. They could produce proper prospective data.”
“So technology can survive without my body.”
“Potentially.”
Good.
That mattered.
Ellie wanted false data removed.
Not automatic destruction.
---
Then the engineer found something worse.
Sonora’s investor deck claimed the Westbrook case showed “no lasting auditory injury attributable to prolonged controlled vibration.”
That statement was not supported.
Ellie had underlying hearing impairment before? Possibly evolving, but exact contribution of device was never completely known.
No one could say it caused no lasting injury.
Claire’s face went cold.
“They are converting uncertainty into safety.”
Exactly.
The same mistake from fifteen years earlier, reversed.
Before:
A prior diagnosis had convinced doctors not to look.
Now:
Incomplete outcome data was being converted into commercial certainty.
Ellie said:
“I want regulatory correction.”
Maya nodded.
“We can notify through counsel.”
“Do it.”
Claire added:
“Westbrook Systems will cooperate.”
Ellie turned.
“Only records requested.”
Claire blinked.
“Right.”
No extra takeover.
Good.
---
Miles Rourke finally requested his own meeting.
Through counsel.
Maya allowed deposition-style interview.
Ellie did not attend initially.
Claire did.
Rourke was sixty-three.
Thin.
Immaculate gray suit.
He had served Westbrook Medical Electronics under Claire’s father.
He looked at Claire and said:
“I never intended to harm your daughter.”
Claire almost laughed.
“Apparently that sentence is hereditary in this case.”
Rourke flinched.
Maya began.
“Did you know a Crestwave prototype had been used in a pediatric patient?”
“Not at time of surgery.”
“When did you learn?”
“Months later.”
“How?”
“Dr. Voss requested records consolidation.”
“Did you ask whether use was approved?”
“Yes.”
“What were you told?”
“That Gerald had authorized family research participation.”
“Claire?”
Rourke paused.
“I was shown consent.”
“The composite?”
“I did not know it was composite.”
“Did you verify?”
“No.”
“Why?”
“Gerald was family trustee and board representative.”
Claire stared.
Again.
Authority became substitute for verification.
“Did you preserve archive?”
“Yes.”
“Why tell investigators years later no clinical archive survived?”
Rourke’s jaw tightened.
“Because by then the company had been sold twice and records were fragmented.”
Maya slid acquisition list.
“You personally bought nineteen boxes and seven servers from bankruptcy estate.”
Silence.
“Did you?”
“Yes.”
“Before internal interview?”
“After.”
Timeline mattered.
He had not possessed at interview.
Maybe he truly didn't know where records were then.
“Why buy?”
Rourke looked toward lawyer.
“Because I believed the technology still had value.”
There.
“Did you disclose to Claire’s investigation later?”
“No.”
“Why?”
“I did not believe the archive changed Gerald or Voss liability.”
“Did it contain consent packet?”
“Yes.”
“Did you know authenticity questionable?”
“No.”
“When did you sell to Sonora?”
“Seven years ago.”
“For how much?”
“Three point eight million.”
Claire stared.
Rourke personally made millions from archive containing Ellie’s data.
“Did you disclose medical-record origin?”
“I disclosed research materials.”
“That was not question.”
He hesitated.
“Not specifically.”
Maya leaned.
“Did you obtain Ellie’s authorization?”
“No.”
“Claire’s?”
“I believed existing consent controlled.”
“Did you consult independent privacy counsel?”
“Yes.”
That surprised.
“Who?”
Rourke named firm.
They requested copy.
Counsel opinion stated:
Use acceptable if source consent valid and records sufficiently de-identified.
Conditional.
If valid.
Rourke never verified validity.
Convenient.
---
Then Maya asked:
“Why did you call it the Westbrook Pediatric Case in materials sold to Sonora?”
Rourke’s face changed.
“Because that is what internal archive called it.”
“So you knew identity.”
“Yes.”
“Did Calder?”
Another pause.
“Yes.”
There.
Sonora knew exactly whose case.
Not anonymous.
Maybe they removed name externally but internal knowledge existed.
“Did Calder know Ellie had never agreed?”
“I told him there had been litigation.”
“What did he say?”
Rourke looked down.
“He said controversy does not invalidate data.”
Claire’s expression turned dangerous.
Maya kept control.
“What else?”
“He said history is messy.”
Then:
“And if the technology helps thousands, no one will care where one old dataset came from.”
Silence.
There.
Not forged signature by Calder.
Not secret implantation.
But a present-day choice.
He knew consent history questionable.
He used anyway.
---
Ellie listened to recording later.
When Calder’s sentence played, she removed hearing devices.
Not because overwhelmed by sound.
Because she wanted quiet while deciding.
Maya asked:
“What do you want next?”
Ellie signed first.
INJUNCTION AGAINST USE OF MY DATA.
Then spoke.
“And I want them to stop clinical trial until regulatory review confirms no unsupported safety claim depends on me.”
Claire nodded.
Maya continued:
“Money?”
Ellie thought.
“I want legal fees.”
Another.
“If they profited from my data, we’ll address.”
Another.
“But I’m not selling permission retroactively.”
Good.
Then Maya’s phone chimed.
An email from Sonora.
Subject:
URGENT CLINICAL SAFETY MATTER
A trial participant had reported severe pain, tinnitus, and episodes of disorientation while using Auralink S2.
Fifteen-year-old girl.
The adverse event had occurred three weeks earlier.
Sonora had not reported it to all study sites.
Ellie stared.
Her case was no longer only history.
May you like
Somebody was getting hurt now.
And the company using her childhood to claim safety had apparently already started deciding which facts other people were ready to know.
Related Stories
